NCT03950609: Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

NCT03950609
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known unstable symptomatic brain metastases -see trial for details; Patients with prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, deforolimus) and/or lenvatinib
https://ClinicalTrials.gov/show/NCT03950609

Comments are closed.

Up ↑